For millions of people living with advanced eye diseases, the path to preserving vision is often paved with anxiety. The current gold standard for treating proliferative retinopathies—conditions where abnormal blood vessels grow and leak in the retina—requires intravitreal injections. This process involves delivering medication directly into the vitreous humor of the eye, a procedure that many patients find painful and that carries inherent risks of infection, inflammation, and spikes in ocular pressure.
Now, a collaborative research effort between Wayne State University and Washington State University may offer a less invasive treatment for retinopathies by moving the needle from the eye to the bloodstream. The team has developed a “smart” nanocarrier capable of delivering potent medication systemically—via a simple IV or injection elsewhere in the body—even as ensuring the drug only activates at the site of the disease.
The findings, published in the journal Theranostics, describe a breakthrough in targeting the specific vascular malformations that lead to blindness in conditions such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration.
The Challenge of Proliferative Retinopathies
To understand the significance of this delivery system, one must first understand the pathology of proliferative retinopathies. In these diseases, the retina suffers from oxygen deprivation, triggering the growth of new, fragile blood vessels. Although, these vessels are dysfunctional; they are leaky and often merge to form “neovascular tufts.”
These tufts are more than just structural anomalies; they block light from reaching the photoreceptors and can cause severe hemorrhaging or retinal detachment, eventually leading to permanent vision loss. Because the eye is a protected environment, getting medication past the blood-retinal barrier has historically required invasive direct-to-eye injections.
“We have created a nanocarrier called trehalose-based glycodendrimer (Tre-D) that can selectively target aberrant neovascular tufts in the retina using a simple systemic administration, thus eliminating the necessitate for painful intravitreal injections,” said Dr. Nikhlesh K. Singh, associate professor of ophthalmology, visual and anatomical sciences at the Wayne State School of Medicine and corresponding author of the study.
Engineering a ‘Smart’ Delivery System
The core of the innovation lies in the chemistry of the nanocarrier, specifically the use of trehalose. Trehalose is a naturally occurring sugar that, in this application, allows the nanoparticle to act as a homing device. When injected into the bloodstream, the Tre-D carrier ignores healthy vasculature and specifically binds to the damaged, leaky vessels characterizing the retinal tufts.
This precision is critical because of the payload the nanocarrier delivers: Axitinib. Axitinib is a powerful tyrosine kinase inhibitor used to stop the growth of new blood vessels. While highly effective, the drug can be toxic if it circulates freely throughout the body, potentially causing systemic side effects.
By encapsulating Axitinib within the Tre-D nanocarrier, the researchers have created a shield that protects the rest of the body from the drug’s toxicity while ensuring a concentrated dose reaches the diseased retinal tissue. This mechanism effectively transforms a potentially dangerous systemic drug into a localized therapy.
Comparing Treatment Modalities
| Feature | Intravitreal Injection | Tre-D Nanocarrier (Proposed) |
|---|---|---|
| Administration | Directly into the eye | Systemic (IV or subcutaneous) |
| Patient Experience | Painful, high anxiety | Similar to a standard vaccination |
| Primary Risks | Infection, inflammation, pressure | Reduced systemic toxicity via targeting |
| Targeting | General ocular distribution | Selective binding to neovascular tufts |
Implications for Global Health
The potential impact of a systemic, less invasive treatment for retinopathies cannot be overstated. In many parts of the world, access to specialized ophthalmologists capable of performing frequent intravitreal injections is limited. A systemic administration method could theoretically simplify the delivery of care and increase patient compliance, as the fear of needle-to-eye procedures is a significant barrier to treatment adherence.
Dr. Singh noted that in the current medical landscape, there is a distinct lack of effective systemic therapies for these conditions. The Tre-D system represents the first organic nanoparticle capable of localizing to damaged retinal vessels after systemic injection, marking a shift in how clinicians might approach the leading causes of blindness worldwide.
The research was a collaborative effort involving Dr. Anjali Sharma and her team at Washington State University, who assisted in the design and production of the nanoparticle. The efficacy of the Tre-D system was evaluated using a murine model of proliferative retinopathies, demonstrating that the nanocarrier successfully localized to the target areas and inhibited the growth of aberrant vessels.
This research was supported in part by the National Eye Institute of the National Institutes of Health and an unrestricted grant from Research to Prevent Blindness to the Kresge Eye Institute.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a healthcare provider for diagnosis and treatment of eye diseases.
The next phase of development will likely focus on refining the nanocarrier’s efficiency and moving toward larger animal models to further validate safety and efficacy before human clinical trials can be considered. Researchers will continue to monitor the long-term stability of the Tre-D carrier and its performance across different types of proliferative retinopathies.
We invite readers to share their thoughts on this development in the comments below or share this story with those affected by vision loss.
